Obecabtagene Autoleucel
Obecabtagene autoleucel is a personalized cell therapy that reprograms a patient's own immune cells to recognize and destroy cancer cells expressing the CD19 protein. This treatment is used for certain blood cancers, particularly B-cell malignancies that have not responded to other therapies.
A CAR-T cell therapy using the patient's own modified T cells to target and kill CD19-expressing cancer cells.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01XL12
- RxNorm
- 2698195
- Generic
- Obecabtagene Autoleucel
- Class
- atc-l01
- Brands
- Aucatzyl
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Obecabtagene autoleucel is indicated for the treatment of relapsed or refractory B-cell malignancies, including acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma in adult patients who have not responded adequately to prior treatments.
This autologous immunotherapy involves collecting the patient's T cells, genetically engineering them to express a chimeric antigen receptor (CAR) that targets the CD19 protein found on B cells, and then infusing these modified cells back into the patient where they recognize and destroy CD19-expressing cancer cells.
As a CAR-T cell therapy, this medication carries risks of serious side effects including cytokine release syndrome (CRS) and neurotoxicity. Treatment must be administered in qualified healthcare facilities with experience in cell therapy. Regular monitoring for several weeks post-infusion is essential to manage potential adverse reactions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy